Hair loss is one of the dermatological conditions most commonly faced by the dermatologist or general physician. Male pattern hair loss, also known as androgenic alopecia, is shown that occur in about 50% of both sexes. Currently the only Food and Drug Administration(FDA)-approved medications for androgenetic alopecia are finasteride and minoxidil, there continues to be interest in the potential roles of light and laser treatments for hair loss. A number of products using low-energy light beams have been marketed for the promotion of hair growth. For instance, the HairMax LaserComb has obtained FDA approval through in vivo study. Light-emitting diode(LED) and low-level light therapy(LLLT) have recently increased in popularity as a stand-alone or adjunctive treatment. The goal of these devices is to increase the blood flow to the scalp to stimulate the hair organ. Fractional photothermolysis allowed rapid repair of laser-induced thermal injury and induced a significant increase of hair density and fair shaft thickness in patients with male pattern hair loss(MPHL) and female pattern hair loss(FPHL) in pilot clinical trials. Some success has been reported resulting from the paradoxical effects. A variety of laser have been tested in vivo for the treatment including the excimer laser, the helium-neon laser, 1,550-nm fractional erbium-glass laser and 904-nm pulsed infrared diode laser. Dermatologists caution that more scientific data are needed before these new therapeutic devices for hair loss can be recommended. Therefore, these trials could lead to seek even better treatment options or adjuvant modalities in the future.